Article Figures & Data
Figures
- Figure 1.
Cohort enrollment. SLE: systemic lupus erythematosus; HCQ: hydroxychloroquine.
Tables
- Table 1.
Crude OR and 95% CI for associations of 4 WHO dimensions of adherence with adherence ≥ 80% in 1956 Kaiser Permanente patients with SLE and 2 recent prior fills of hydroxychloroquine, Northern California, 2006–14.
Characteristics Adherence ≥ 80%, n = 1132 Adherence < 80%, n = 824 Crude OR 95% CI p Socioeconomic status (block-group) Median household income, thousands 15–54 26.9 28.7 1.00 Ref. 55–74 23.1 23.7 1.21 0.94–1.56 0.13 75–99 24.7 25.3 1.04 0.81–1.33 0.75 100–250 25.3 22.3 1.04 0.81–1.34 0.74 Percent household income below poverty level 0–3.0 24.5 25.5 1.00 Ref. 3.1–6.5 25.9 23.5 1.03 0.80–1.33 0.80 6.6–12.7 24.7 25.9 0.99 0.77–1.28 0.96 12.8–100 24.9 25.1 1.15 0.89–1.48 0.30 Percent unemployed 0–3.7 26.2 24.8 1.00 Ref. 3.8–5.4 25.0 25.6 0.90 0.70–1.15 0.40 5.5–7.2 23.6 23.2 0.97 0.75–1.25 0.79 7.3–22 25.2 26.4 0.92 0.72–1.19 0.54 Percent high school graduate 0–13 26.3 25.0 1.00 Ref. 14–19 21.7 23.5 1.06 0.81–1.38 0.68 20–28 30.1 31.8 0.90 0.71–1.14 0.37 29–59 21.9 19.7 0.87 0.67–1.13 0.30 Patient-related factors Age, yrs ≤ 39 29.4 34.2 1.00 Ref. 40–49 21.0 26.6 0.92 0.72–1.17 0.50 50–64 32.0 25.8 1.44 1.14–1.82 0.00 65–89 17.6 13.4 1.53 1.16–2.03 0.00 Sex Male 10.5 9.0 1.00 Ref. Female 89.5 91.0 0.84 0.62–1.14 0.26 Race/ethnicity African American 15.2 16.9 0.68 0.52–0.89 < 0.01 Asian/Pacific Islander 19.7 21.2 0.70 0.54–0.90 < 0.01 Hispanic 14.1 19.2 0.55 0.42–0.72 < 0.0001 White 41.0 30.8 1.00 Ref. Other/unknown* 2.2 3.2 0.63 0.46–0.86 < 0.001 Language English 93.0 92.3 1.00 Ref. Other 7.0 7.7 0.91 0.64–1.28 0.57 Condition-related factors in the year before index Charlson comorbidity index 0 83.6 84.5 1.00 Ref. 1 9.2 6.9 1.34 0.96–1.88 0.09 ≥ 2 7.2 8.6 0.85 0.61–1.18 0.34 Rheumatology visits 0–1 24.0 29.6 1.00 Ref. 2 26.3 25.1 1.29 1.01–1.65 0.04 ≥ 3 49.7 45.3 1.35 1.09–1.68 0.01 Hospitalization for any cause No 81.6 82.0 1.00 Ref. Yes 18.4 18.0 1.03 0.81–1.30 0.82 eGFR,** ml/min/1.73 m2 30–59 0.7 1.5 0.53 0.22–1.32 0.17 60–89 29.1 21.1 1.52 1.23–1.89 0.0001 ≥ 90 70.2 77.4 1.00 Ref. Therapy-related factors in the year before index Medications (yes vs no) Prednisone 58.0 56.9 1.05 0.87–1.26 0.62 Mycophenolate mofetil 15.6 18.5 0.81 0.64–1.03 0.09 Azathioprine 11.8 11.5 1.03 0.78–1.36 0.83 ACE inhibitor 20.1 18.3 1.12 0.89–1.41 0.32 - Table 2.
Adjusted OR and 95% CI for associations of patient- and condition-related factors* with adherence ≥ 80% in 1956 Kaiser Permanente patients with SLE and 2 recent prior fills of hydroxychloroquine, Northern California, 2006–14.
Variables Adjusted OR 95% CI p Age, yrs ≤ 39 1.00 Ref. 40–49 0.92 0.72–1.18 0.51 50–64 1.39 1.09–1.76 0.01 65–89 1.44 1.07–1.93 0.02 Race African American 0.74 0.56–0.97 0.03 Asian/Pacific Islander 0.76 0.59–0.99 0.04 Hispanic 0.59 0.44–0.77 < 0.001 White 1.00 Ref. Other/unknown 0.67 0.49–0.92 0.01 No. rheumatology visits 0–1 1.00 Ref. 2 1.30 1.01–1.67 0.04 ≥ 3 1.47 1.18–1.83 < 0.001 ↵* Other factors in Table 1 were not associated with adherence to a significant degree in the adjusted model. The rheumatologist and the medical center also were not associated with adherence to a significant degree in the adjusted model. SLE: systemic lupus erythematosus.
